Cancer patients get chance to continue promising treatment
Disease control
Not yet recruiting
This study allows cancer patients who are already benefiting from RVU120 treatment in a previous trial to continue receiving it. It aims to monitor safety and track how long patients can stay on the treatment. Only 10 participants who show continued benefit and cannot access stan…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC